Home > News > BioSante Pharmaceuticals Announces Results
August 16th, 2004
BioSante Pharmaceuticals Announces Results
BioSante reported a net loss of approximately $2.6 million (or $0.15 per share) for the quarter, compared to a net loss of approximately $1.6 million (or $0.18 per share) for the same period in 2003. The increased total net loss was due primarily to increased expenses related to development of the company's hormone therapy products, including the ongoing Phase III clinical trial of Bio-E-Gel(TM) (bioidentical estradiol gel) for the treatment of menopausal symptoms.
Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014
Industrial Nanotech, Inc. to Publish PCAOB Audited Financials July 31st, 2014
Nanometrics Reports Second Quarter 2014 Financial Results July 30th, 2014
Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014